The results of a previous study verified that umbilical cord mesenchymal stem cells (UCMSCs) have good therapeutic effects for the treatment of HBV-related acute-on-chronic liver failure (ACLF) and liver cirrhosis (LC). Nevertheless, it is still unknown whether the effects of UCMSCs are affected by recipient age. Patients treated with UCMSCs who met the criteria of HBV-related ACLF and liver cirrhosis were identified in this retrospective observational study. Patients were divided into subgroups according to the World Health Organization (WHO) age criteria (< 45 vs. ≥ 45 years). Group A included young ACLF patients (< 45 y), and group B included older ACLF patients (≥ 45 y). Young LC patients (< 45 y) were assigned to group C, and group D included older LC patients (≥ 45 y). Patients’ clinical characteristics, demographics, biochemical factors, and model for end-stage liver disease (MELD) scores were compared for 24 weeks. Sixty-four ACLF patients and 59 LC patients were enrolled in this study. Compared with patients in groups B and C, patients in group A did not show significant superiority in terms of the levels of ALT, AST, TBIL, AFP, and PTA and MELD scores. However, the median decrease and cumulative decrease in the TBIL and ALT levels of patients in group C were larger than those of patients in group D after four weeks of UCMSC transfusions. For older patients (≥ 45 y), the cumulative decrease and the median decrease in the TBIL of ACLF patients were significantly greater than those of LC patients after UCMSC treatment. However, the median decrease in ALT levels of ACLF patients was significantly greater than that of LC patients during UCMSC treatment, and the cumulative decrease in ALT levels of ACLF patients was significantly greater than that of LC patients at all time points. The therapeutic effects of UCMSCs for HBV-related acute-on-chronic liver failure and liver cirrhosis varied partly by patient age. Assessing patient age is necessary prior to UCMSC clinical use.

中文翻译：

---

受者年龄对脐带间充质干细胞对HBV相关慢加急性肝功能衰竭和肝硬化的影响

既往研究结果证实，脐带间充质干细胞（UCMSCs）对治疗HBV相关的慢加急性肝衰竭（ACLF）和肝硬化（LC）具有良好的疗效。然而，UCMSCs 的作用是否受受体年龄影响尚不清楚。在这项回顾性观察研究中确定了接受 UCMSCs 治疗的符合 HBV 相关 ACLF 和肝硬化标准的患者。根据世界卫生组织 (WHO) 的年龄标准（< 45 对 ≥ 45 岁）将患者分为亚组。A 组包括年轻 ACLF 患者（< 45 岁），B 组包括老年 ACLF 患者（≥ 45 岁）。年轻的 LC 患者（<45 岁）被分配到 C 组，D 组包括老年 LC 患者（≥45 岁）。患者的临床特征、人口统计学、生化因素和终末期肝病模型 (MELD) 评分进行了 24 周的比较。64 名 ACLF 患者和 59 名 LC 患者参加了这项研究。与B、C组患者相比，A组患者在ALT、AST、TBIL、AFP、PTA和MELD评分水平方面均无明显优势。然而，在输注 UCMSC 4 周后，C 组患者 TBIL 和 ALT 水平的中位下降和累积下降幅度大于 D 组患者。对于老年患者（≥ 45 岁），ACLF 患者 TBIL 的累积下降和中位下降明显大于 UCMSC 治疗后的 LC 患者。然而，在 UCMSC 治疗期间，ACLF 患者 ALT 水平的中位下降明显大于 LC 患者，ACLF 患者 ALT 水平的累积下降幅度均显着大于 LC 患者。UCMSCs 对 HBV 相关的慢加急性肝衰竭和肝硬化的治疗效果在一定程度上因患者年龄而异。在 UCMSC 临床使用之前评估患者年龄是必要的。